Vaginal Dryness, GSM & Sex After Menopause: What Changes, What Helps, and What’s Worth Treating

Dryness may be the first change you notice. Burning, irritation, pain during sex and urinary symptoms can also be part of genitourinary syndrome of menopause (GSM), a group of symptoms linked to estrogen-related changes in pelvic tissues. Symptoms often persist over time and may need treatment.

The older term “vaginal atrophy” gives the impression that the changes are confined to the vagina. GSM is a broader term because declining estrogen can affect the vulva, vagina, urethra and bladder during and after the menopause transition.

Symptoms can be deceptively varied. One woman notices dryness during sex. Another develops burning that repeatedly tests negative for yeast. Someone else suddenly needs to urinate frequently or begins having recurrent urinary tract infections. There may be tearing at the opening, spotting after penetration, itching, altered discharge, reduced lubrication or simply a sense that the tissues feel different.

These are not separate systems coincidentally malfunctioning at the same age. The vagina, vulva, urethra and bladder are all influenced by estrogen. GSM also differs from many menopause symptoms because it often persists or progresses without treatment.

IN THIS ARTICLE +

1. What estrogen was doing all along
2. GSM can affect more than the vagina
3. Dryness during sex is not always GSM
4. Moisturizer and lubricant are not the same
5. Choosing a lubricant: water, silicone or oil?
6. Vaginal estrogen: small dose, local treatment
7. I’m using vaginal estrogen, but I’m still uncomfortable. What now?
8. What if you have had breast cancer?
9. What about vaginal “rejuvenation” lasers and radiofrequency?
10. Libido and GSM are not the same problem
11. Recurrent UTIs deserve special attention
12. Douching and “feminine hygiene” can make things worse
13. A practical GSM plan
14. When to arrange medical care
15. The Maple Menopause bottom line
16. References and further reading

What estrogen was doing all along

Before menopause, estrogen helps maintain tissue structure, blood supply, elasticity and moisture, and it influences the vaginal microbiome. Estrogen supports mature vaginal epithelial cells and glycogen-derived substrates that help Lactobacillus species. These bacteria produce lactic acid and contribute to the normally acidic reproductive-age vaginal environment.

As estrogen declines, tissue can become thinner and less elastic, glycogen falls, lactobacilli may become less dominant and vaginal pH commonly rises. Blood flow and secretions may decrease. This is not simply “less lubrication”; it is a change in tissue structure and ecology. Canadian SOGC guidance includes dryness, irritation, painful intercourse and urinary symptoms among GSM manifestations and recognizes both non-hormonal and hormonal management.

GSM can affect more than the vagina

• Vaginal dryness, burning, itching or irritation
• Reduced lubrication with sexual activity
• Pain with penetration
• Tenderness or tearing around the vaginal opening
• Spotting or bleeding after sex
• Urinary urgency or frequency
• Burning with urination
• Recurrent urinary tract infections

Some women experience mainly urinary symptoms and do not connect them with menopause. Estrogen receptors are present in the lower urinary and genital tracts, which helps explain why vaginal estrogen may be recommended to reduce recurrent UTIs after menopause. It does not treat an active bacterial infection; it improves the genitourinary environment that helps resist future infection.

Dryness during sex is not always GSM

Lubrication and sexual comfort can also be affected by medications, pelvic-floor muscle tension, vulvar skin conditions, infection, cancer treatment, pelvic surgery, relationship context, anxiety, pain conditions and sexual arousal. Treating everything as “vaginal dryness” can delay the right diagnosis.

Persistent vulvar itching should not automatically trigger repeated yeast treatment. Conditions such as lichen sclerosus can occur in midlife and need assessment. Likewise, new bleeding after menopause requires appropriate evaluation rather than being attributed to fragile tissue.

Moisturizer and lubricant are not the same

A vaginal moisturizer is used regularly—often several times a week—to support ongoing moisture and comfort. A lubricant reduces friction during sexual activity. It works immediately but is not primarily designed to change baseline moisture between encounters. Many women use both.

Marketing can blur the distinction. A “feminine moisturizer,” “intimate wash,” “pH-balancing gel” or “menopause serum” is not necessarily a vaginal moisturizer in the clinical sense. Read what the product is actually designed to do.

Choosing a lubricant: water, silicone or oil?

Water-based

Widely available, easy to wash away and generally compatible with condoms and sex toys. Some formulas become sticky or dry quickly, so reapplication may be needed.

Silicone-based

Usually remain slippery longer and can be helpful when friction is substantial or for sex in water. They may not be compatible with some silicone toys; check the manufacturer’s instructions.

Oil-based

Can provide long-lasting lubrication, but oils damage latex condoms and increase failure risk. Products not formulated for vaginal use may irritate some people.

Stop using anything that burns or stings. Warming, cooling, tingling and heavily fragranced formulas can be unpleasant on already-sensitive tissue.

Osmolality and pH: details the advertising skips

Lubricant formulation can affect tissue. Very hyperosmolar products can draw water out of epithelial cells and have shown cellular and tissue effects in laboratory research. For most shoppers, calculating chemistry in a store aisle is unrealistic. Choose a simple product intended for vaginal use, avoid formulas that sting or irritate, and change products if one causes trouble. More ingredients and fragrance are not necessarily better.

Hyaluronic-acid vaginal moisturizers

Hyaluronic acid is a water-binding molecule used in some non-hormonal vaginal moisturizers. Studies suggest these preparations can improve GSM symptoms, and some trials found improvement comparable with vaginal estrogen for certain outcomes, although estrogen has a much larger evidence base and formulations vary.

This makes hyaluronic-acid moisturizers a reasonable non-hormonal option for women who prefer to start without hormones or cannot use estrogen. “Contains hyaluronic acid” does not automatically make every intimate cosmetic evidence-based; research evaluates particular formulations and schedules.

Vaginal estrogen: small dose, local treatment

For persistent or moderate-to-severe GSM, low-dose vaginal estrogen is among the most effective treatments. It is available as tablets or inserts, creams and rings, with Canadian availability varying. Unlike systemic menopausal hormone therapy, low-dose vaginal estrogen is intended primarily for local genitourinary tissue.

Improvement may take weeks and ongoing treatment is generally needed to maintain benefit. Systemic absorption can occur, especially early when tissue is very thin, but exposure with recommended low-dose vaginal products is generally much lower than with systemic estrogen.

“I am already on HRT. Why am I still dry?”

Systemic hormone therapy can help GSM for some people but does not reliably eliminate it. Some women using systemic estrogen still need local treatment. That does not mean their systemic therapy has failed; hot flashes and vaginal tissue are different treatment targets.

Do you need progesterone with low-dose vaginal estrogen?

Specialist guidelines generally do not require routine progestogen solely for recommended low-dose local vaginal estrogen. Canadian product labels are not fully aligned with that advice: the Premarin cream, Estragyn and Estring monographs reviewed advise progestin protection when the uterus is present. Dose and formulation matter, and this guidance does not replace the protection required with systemic estrogen. Ask your prescriber to explain the plan for your exact product. Our Canadian comparison of vaginal creams, tablets and rings covers strengths, schedules, label differences and costs. Unexpected postmenopausal bleeding still requires assessment.

I’m using vaginal estrogen, but I’m still uncomfortable. What now?

When everyone else’s treatment sounds miraculous, an unfinished response can feel like a personal failure. It is better understood as a reason to review the plan. Where the discomfort sits, how long you have used treatment and what has changed are more useful than simply deciding that estrogen does or does not work.

Some relief may appear within weeks, while fuller improvement can take around three months. Early gains might be less chafing in clothes or less stinging with wiping, rather than an immediate return to comfortable penetration. Agree on a follow-up point with your prescriber. If there is no worthwhile improvement by about three months, or symptoms worsen sooner, ask for reassessment rather than persevering indefinitely. NHS guidance explains the expected treatment timescale.

Bring the actual package or a photograph to a pharmacist or prescriber. Ask them to check the prescribed schedule, any initial treatment phase, applicator use, missed applications and whether the preparation reaches the area being treated. Explain if insertion is painful, the cream leaks or the routine is difficult to sustain. Cream, tablet and ring instructions differ; there is no universal internet schedule. Do not independently increase frequency, restart a loading regimen or change where you apply a prescription product.

Match the next step to the symptom

• Still dry: discuss how much improvement is realistic and whether a regular vaginal moisturizer can complement treatment. Lubricant still has a role during sexual activity. Neither needing lubricant nor having less discharge automatically proves treatment failure.
• Still burning: say whether this is external skin, the vaginal opening, deeper discomfort or burning during urination. Contact irritation, infection and vulvar skin disease can coexist with GSM. Persistent symptoms warrant examination and testing where indicated; repeating yeast treatments without a diagnosis can muddy the picture.
• Sex remains painful: stop painful penetration and describe whether pain is at entry or deeper. Tissue fragility, scarring, pelvic-floor overactivity and other pelvic conditions need different care. Comfortable nonpenetrative intimacy is an option while the cause is addressed, not a consolation prize.
• Urinary symptoms persist: ask whether an episode needs a urine sample and whether GSM, infection, overactive bladder or pelvic-floor dysfunction fits. Vaginal estrogen helps reduce recurrent UTI risk in appropriate patients; it is not an antibiotic. Fever, flank pain, vomiting, visible blood in urine or feeling very unwell needs prompt assessment.
• Symptoms improve but return: review maintenance use, supply interruptions and any new products or health changes. GSM often needs ongoing treatment, but a new symptom should not simply trigger a larger dose.
• Treatment causes irritation: report the timing and duration after each application. A reaction may relate to the preparation or another condition; it does not identify an estrogen allergy by itself. Ask whether a different formulation is appropriate. Severe or persistent burning is not something you must endure to earn a benefit.

The 2025 AUA/SUFU/AUGS GSM guideline emphasizes reassessment and individualized care. A partial response may mean that more than one condition is present. It does not mean every ongoing symptom needs more hormone.

When the diagnosis needs another look

Lichen sclerosus can cause soreness, itch, fragile skin, white patches or changes in vulvar shape and needs specific treatment and follow-up. You cannot rule it in or out from a photograph at home. Vulvodynia is persistent vulvar pain assessed after other explanations have been considered; the skin may look relatively normal. An examination should be explained, consented to and stopped if you ask. You can request a slower approach, a support person or an appropriate referral.

An overactive pelvic floor can remain guarded even after tissue dryness improves. Adding repeated Kegels may increase discomfort if the problem is difficulty relaxing. A pelvic-health physiotherapist can assess whether relaxation, coordination, graded rehabilitation or strengthening is appropriate. This complements medical care; it does not substitute for investigating bleeding, skin changes or infection.

For the appointment, write down the main symptom and its location; the treatment name, start date and actual use; what improved; what still limits daily life; and what happens after application. Finish with one direct question: Could this be GSM plus something else, and when should we reassess? That short note is usually more useful than another daily symptom score.

What if you have had breast cancer?

This needs individualized discussion, not a blanket internet answer. Non-hormonal moisturizers and lubricants are generally tried first. When symptoms remain significant, major guidelines allow consideration of low-dose vaginal estrogen for selected breast-cancer survivors after discussion of risks, benefits, treatment and individual circumstances.

The conversation is especially nuanced for women using aromatase inhibitors, which intentionally suppress estrogen to very low levels. The useful message is neither “always forbidden” nor “completely risk-free.” It is that severe GSM deserves treatment and shared decision-making.

Vaginal DHEA and other prescription options

Prasterone (DHEA) is used vaginally and converted locally into active sex steroids within tissue; it has been studied for moderate-to-severe painful sex associated with menopause. Canadian prescription options also include prasterone (Intrarosa) and oral ospemifene (Osphena), a selective estrogen receptor modulator. They have different indications, risks and restrictions and are not interchangeable substitutes for vaginal estrogen. Canadian availability, stock and coverage should be confirmed with a pharmacist; a US brand or over-the-counter claim on a forum may not apply here.

What about vaginal “rejuvenation” lasers and radiofrequency?

Marketing has raced ahead of evidence. Energy-based treatments are promoted for dryness, painful sex, urinary symptoms and “rejuvenation,” often at substantial cost. Evidence for effectiveness and long-term safety is less convincing than the advertising, and major organizations urge caution outside appropriate clinical or research settings.

Expensive and technologically impressive do not automatically mean better supported than vaginal estrogen or moisturizers.

Pelvic-floor physiotherapy: especially when penetration hurts

Painful sex is not always only a lubrication problem. After repeated pain, pelvic-floor muscles may guard against anticipated penetration and become difficult to relax. More lubricant may not solve this.

A pelvic-floor physiotherapist can assess muscle tone, coordination, scar tissue and pain patterns. Treatment may involve education, relaxation, manual techniques, exercises and gradual exposure—not simply more Kegels. An overactive painful pelvic floor may need relaxation rather than strengthening.

Vaginal dilators: a tool, not a punishment

Graduated dilators can help some women with narrowing, pain, pelvic-floor guarding or difficulty with penetration, including after cancer treatment. The goal is not to force tissue open or tolerate pain. Used gently—sometimes with physiotherapy guidance—they can help tissue and muscles accommodate comfortable penetration. Pain is information, not an achievement target.

Sex itself does not “keep your vagina young”

Sexual arousal increases genital blood flow, and regular comfortable partnered or solo sexual activity may support function and flexibility. But no one should feel obliged to have painful penetrative sex as medical treatment. Pushing through pain can reinforce guarding and avoidance. Treat dryness, tissue changes and pain first. Sex is allowed to be pleasurable rather than physiotherapy assigned by the internet.

Pressure or a bulge is a different assessment question. Our pelvic organ prolapse guide explains examination, physiotherapy, support pessaries and surgical options. Vaginal estrogen may help accompanying GSM but does not repair a prolapse.

Pain, comfort and desire can overlap without being the same problem. See Sex, Desire & Menopause for the desire and arousal side of the conversation.

Libido and GSM are not the same problem

Desire is influenced by hormones, medications, mood, sleep, stress, relationship context, body image, pain, health, sexual history and whether the sex on offer is actually enjoyable. GSM can crush desire for an understandable reason: if sex hurts, the brain becomes less enthusiastic.

Treating pain may indirectly improve interest, but vaginal estrogen is not a universal libido drug. Someone can also have healthy tissue and low desire. The distinction matters because the solutions differ.

Recurrent UTIs deserve special attention

Recurrent UTIs become more common after menopause. For peri- and postmenopausal women with recurrent infections, clinical guidance supports vaginal estrogen to reduce future risk when appropriate. It does not treat an active UTI.

Burning, urgency and frequency also overlap with GSM, pelvic-floor dysfunction and other bladder conditions. If symptoms keep returning, establish whether episodes are culture-confirmed infections, GSM symptoms or a combination rather than repeatedly self-diagnosing.

Douching and “feminine hygiene” can make things worse

The vagina does not require perfume, deodorant, steaming, detox pearls or internal washing. Douching disturbs the environment; fragrance can irritate sensitive vulvar tissue. Gentle external washing with water is usually sufficient. If cleanser is desired, use a small amount of mild fragrance-free product externally. Do not wash inside the vagina.

A new persistent odour or abnormal discharge deserves investigation—not increasingly aggressive cleaning. The separate guide to menopause, body odour and vaginal odour helps identify where the change may be coming from.

What about probiotics and boric acid?

Vaginal probiotics

Products vary by strain, dose and route, and evidence is not strong enough to treat an arbitrary probiotic as a substitute for established GSM care. “10 billion probiotics” says little about whether the organisms have evidence for the problem being treated.

Boric acid

Boric acid has legitimate uses for selected recurrent or difficult-to-treat vaginal infections under guidance. It is not routine treatment for GSM, dryness or menopausal odour. It can be toxic if swallowed and must be stored safely away from children and pets.

Leakage can irritate vulvar skin too

Even small amounts of urine repeatedly contacting vulvar skin can contribute to irritation, burning and odour. Pads may add friction and trap moisture. Changing damp products promptly, choosing breathable options, protecting irritated external skin when appropriate and seeking assessment for incontinence can all be part of vulvar care. Leakage is common—and treatable.

A practical GSM plan

1. Identify the symptoms. Dryness, burning, itching, pain, urgency, UTIs and bleeding point toward different evaluation needs.
2. Remove irritants. Stop douching, fragranced washes, sprays and products that sting.
3. Use lubricant for friction. Use enough and reapply; consider silicone if water-based formulas dry too quickly.
4. Consider moisturizer for ongoing dryness. Regular maintenance differs from lubricant used only during sex.
5. Do not push through pain. Persistent painful penetration deserves assessment; pelvic-floor physiotherapy may help.
6. Discuss vaginal estrogen if symptoms persist. It is among the most effective GSM treatments and may be appropriate even without systemic HRT.
7. Investigate recurrent urinary symptoms. Repeated presumed UTIs can conceal GSM or another bladder or pelvic-floor condition.
8. Reassess. If treatment is not working, reconsider the diagnosis rather than buying endless new products.

When to arrange medical care

Seek assessment for any bleeding after menopause; unexplained bleeding after sex; persistent or worsening vulvar or vaginal pain; sores or ulcers; significant itching; unusual discharge; a distinctly new persistent odour; recurrent urinary symptoms; visible vulvar skin changes; persistent difficulty with penetration; or symptoms that do not improve with reasonable first-line measures. New symptoms after a new sexual partner may warrant STI testing.

References and further reading

Canadian resources

• SOGC Guideline No. 422b — Menopause and Genitourinary Health
• Government of Canada — Women and Diversity Health Guide to Menopause
• AUA/CUA/SUFU Guideline — Recurrent uncomplicated UTIs in women
• Health Canada — Drug Product Database

Clinical and scientific resources

• The Menopause Society — Genitourinary Syndrome of Menopause
• ACOG — Urogenital symptoms after estrogen-dependent breast cancer
• 2025 AUA/SUFU/AUGS GSM guideline executive summary
• 2020 GSM position statement